Invesco Global Listed Private Equity ETF logo

Invesco Global Listed Private Equity ETF (PSP)

Market Closed
17 Jul, 20:00
ARCA ARCA
$
58. 51
-0.22
-0.3746%
$
268.92M Market Cap
14.07% Div Yield
12,200 Volume
$ 58.73
Previous Close
Add Transaction
Day Range
58.43 59.1
Year Range
54.12 72.97
Want to track PSP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
PSP Swiss Property AG (PSPSY) Discusses Richtipark Disposal and Increase in EBITDA Guidance Transcript

PSP Swiss Property AG (PSPSY) Discusses Richtipark Disposal and Increase in EBITDA Guidance Transcript

PSP Swiss Property AG (PSPSY) Discusses Richtipark Disposal and Increase in EBITDA Guidance Transcript

Seekingalpha | 2 weeks ago
3 Thoughts on Retail Advisors & Private Equity for 2H

3 Thoughts on Retail Advisors & Private Equity for 2H

Retail investing has long proved a tantalizing prospect for private equity players. Traditionally a space for limited partners with huge asset pools, like family offices, endowments, pension programs, high net worth individuals (HWNI) and more, private equity funds saw their doors open just slightly more to retail investors in May.

Etftrends | 11 months ago
PSP: Stay Away From This ETF, Strong Sell

PSP: Stay Away From This ETF, Strong Sell

PSP is a strong sell due to persistent underperformance versus SPY and its high expense ratio, eroding any potential alpha. Private equity exposure can be achieved more efficiently by directly holding top players like Blackstone, KKR, and Ares, avoiding ETF fees. PSP's asset mix dilutes returns by combining best-in-class managers with weaker players, resulting in subpar performance.

Seekingalpha | 1 year ago
PSP: An Efficient Avenue to Private Equity Access

PSP: An Efficient Avenue to Private Equity Access

The investing landscape is littered with vehicles that have auras of exclusivity. It feels as though it's off-limits to ordinary investors.

Etftrends | 1 year ago
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025.

Seekingalpha | 1 year ago
PSP: Not My Preferred Private Markets Play

PSP: Not My Preferred Private Markets Play

The Invesco Global Listed Private Equity ETF offers exposure to the private markets industry via publicly traded vehicles. PSP has delivered relatively weak historical performance for investors relative to the broader market. The ETF is highly diversified and includes significant exposure to BDCs.

Seekingalpha | 1 year ago